. 2006 Aug;65(8):983–989. doi: 10.1136/ard.2005.043257

Table 2 Published reports of HBV reactivation in patients with rheumatic disease treated with non‐biological immunosuppressive drugs*.

Patient No	Reference	Diagnosis	Age/sex	Immunosuppressive regimen	Time to flare	Treatment and outcome
1	31	RA	72/F	MTX, 4 mg/week 2 years	60 days†	IFN, GC, CsA
1	31	RA	72/F	PSL, 5 mg/day	60 days†	Died

2	32	RA	75/F	MTX, 7.5 mg/week	15 days†	Plasmapheresis, IFN
2	32	RA	75/F	PSL, 5 mg/day	15 days†	Died

3	34	RA	67/M	MTX, 7.5 mg/week	21 days†	GC
3	34	RA	67/M	PSL, 5 mg/day	21 days†	Died

4	30	RA	57/F	MTX, 7.5–10 mg/week	41 days†	Liver transplant
4	30	RA	57/F	PSL, 5 mg/day	41 days†	Alive

5	4	RA	58/F	MTX, 15 mg/week	2 years chronic treatment	LAM
5	4	RA	58/F	PSL, 7.5 mg/day	2 years chronic treatment	Alive

6	33	PM	57/F	PSL, 40 mg/day	40 days chronic treatment	IFN, CsA
6	33	PM	57/F	PSL, 40 mg/day	40 days chronic treatment	Recovered

7	29	Behçet's disease	43/M	Cyclo, IVMP	2 years chronic treatment; 10 days†	GC
7	29	Behçet's disease	43/M	Cyclo, IVMP	2 years chronic treatment; 10 days†	Died

* Baseline serology in each case was HBsAg+ HBeAg−; †indicates time between discontinuation or reduction of immunosuppressive therapy and hepatitis B flare.

RA, rheumatoid arthritis; PM, polymyositis; F, female; M, male; MTX, methotrexate; PSL, prednisone or prednisolone; Cyclo, cyclophosphamide; IVMP, intravenous methyprednisolone; IFN, interferon; GC, glucocorticoids; CsA, ciclosporin A; LAM, lamivudine.